Basic and clinical studies on teicoplanin in respiratory infections

Hiroshi Fukuhara, Jun Inadome, Tomokazu Kakazu, Hiroaki Nakamura, Hiroshi Kaneshima, Atsushi Saito, Nobuchika Kusano, Isamu Nakasone, Yoshiko Furugen, Shinkou Taira, Seitetsu Hokama

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


We performed basic and clinical studies on teicoplanin (TEIC), a new glycopeptide antibiotic, and the following results were obtained. 1. Antimicrobial activity The minimum inhibitory concentrations (MIC) of TEIC against a total of 432 clinically isolated strains of 6 species were measured and compared with those of vancomycin, minocycline, erythromycin, clindamycin, ofloxacin, imipenem, rifampicin (RFP), clarythromycin and tosufloxacin, using the MIC-2000 System (Dynatech Laboratories). The MIC90 of TEIC was 0.78 μg/ml against methicillin-resistant Staphylococcus aureus (MRSA), and TEIC showed stronger bactericidal activity than other antibiotics except RFP. TEIC showed much activity than other antibiotics against other gram-positive bacteria. 2. Clinical study results TEIC was given five patients (3 cases of pneumonia, one of pleuritis and one of lung abscess) with respiratory infection. The clinical results were good in 3 and unknown in 2. No adverse reactions or abnormal laboratory findings were observed. From the above results, we consider that TEIC to be a useful antibiotics for the treatment of MRSA and gram-positive bacteria in respiratory tract infections.

Original languageEnglish
Pages (from-to)207-211
Number of pages5
Publication statusPublished - 1993
Externally publishedYes


  • MRSA
  • Teicoplanin

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology


Dive into the research topics of 'Basic and clinical studies on teicoplanin in respiratory infections'. Together they form a unique fingerprint.

Cite this